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ALCOHOL-DEPENDENT PATIENTS
Annemans L, Vanoverbeke N
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OBJECTIVES: To conduct a cost analysis of acamprosate
in maintaining abstinence in weaned alcoholic patients in
Belgium.
METHODS: The analysis was based on a state-transition
approach, comparing the use of acamprosate versus “do-
ing nothing” (no pharmaceutical maintenance treatment)
in alcoholic patients after detoxification. The analysis
considered the probability of additional relapses over a
period of 24 months. Clinical data with regard to relapse
rates were obtained from a controlled double-blind trial
by Witworth et al. (1996) (n  448), involving 12 months
treatment with acamprosate and 12 months follow-up.
This trial showed that the advantage of acamprosate over
placebo in preventing relapse continued during the 12
months after cessation of treatment. Treatment patterns
and resource utilization in first line were retrieved from a
Belgian survey among 129 GPs. Data on resource utiliza-
tion in second line were available from a large, open
pragmatic prospective Belgian trial (n  582). Costs were
calculated from the perspective of health insurance. Unit
costs were obtained from official listing and hospital sta-
tistics.
RESULTS: Net cost savings of 21,301 BEF per patient
were obtained over a 24-month period for acamprosate
at a daily cost of 78.6 BEF for the health insurance com-
pared with “doing nothing.” Most savings were obtained
by avoiding acute hospitalizations for detoxification and
institutionalized rehabilitation. Various sensitivity analy-
ses showed a large robustness of the conclusions. A glo-
bal anticipated net saving of 70 million BEF for the Bel-
gian healthcare sector over 2 years was estimated.
CONCLUSIONS: The results of our analysis show that
acamprosate is a cost-saving intervention in maintaining
abstinence in weaned alcoholic patients, if applied during
a period of 12 months after detoxification.
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While measurement of health-related quality of life
(HRQOL) has become a vital part of assessing the effects of
migraine treatment in many international studies, a measure
that is well translated and cross-culturally adapted has not
been available. The 16-item Migraine-Specific Quality of
Life Questionnaire (MSQ) (Version 2.0), which assesses as-
pects of health primarily affected by migraines (initially de-
veloped in US English), has been culturally adapted into 14
languages from Europe and Canada. The translation pro-
cess of the MSQ was coordinated by a quality of life (QoL)
specialist in each target country and followed a rigorous
methodology that consisted of: 1) two separate forward
translations produced by professional translators, native
speakers of the target language and bilingual in English; 2)
comparison and reconciliation of the translations by QoL
specialist and translators; 3) a backward translation by a
native English speaker; 4) comparison of source with back-
ward version; 5) comprehension test in a sample target pop-
ulation; and 6) international harmonization. A number of
conceptual and linguistic issues relating to the concept of
“migraine,” “migraine attack,” and “migraine headache,”
and the meaning of the expression “daily activities,”
emerged during the translation process. A literal translation
of idiomatic expressions such as “let someone down” was
also not always possible; most languages referred to “disap-
point.” Likewise, the literal translation of “social activi-
ties,” referring to humanitarian work in certain languages,
required a descriptive equivalent. Several language-specific
changes were made to resolve each issue during interna-
tional harmonization. The MSQ (Version 2.0) was trans-
lated into 14 languages for use in international studies. A
rigorous translation methodology was performed to ensure
that the translated versions were conceptually equivalent to
the source version and were cross-culturally valid. Psycho-
metric testing will be conducted in the future to ensure reli-
ability and validity in each translation.
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COST-UTILITY ANALYSIS OF LAPAROSCOPIC 
VERSUS OPEN SURGERY FOR COLONIC 
DISEASE
Eypasch E, Köhler L, Tschubar F, Troidl H, Lauterbach KW
St. Hildegardis Hospital, II, US; Department of Surgery, 
University of Cologne, Cologne, Germany; and Institute for 
Health Economics at the University of Cologne,
Cologne, Germany
OBJECTIVES: The cost of laparoscopic colonic surgery
is dominated by expenses for disposable instruments. The
utility of this surgery in terms of quality of life has not
been well documented. The two variables of costs versus
quality of life were evaluated in a multi-institutional pro-
spective trial.
METHODS: In two academic departments of surgery with
the same level of skill for endoscopic surgery, patients were
prospectively assigned to have either open (N  27) or lap-
aroscopic (N  35) surgery for sigmoid diverticulitis or co-
lon cancer. Quality of life (QoL) was assessed by three dif-
ferent instruments: SF-36, EuroQol, and Gastrointestinal
Quality of Life Index (GIQLI). Costs were evaluated using
a standardized protocol where all resources were directly
assigned to the individual patient and procedure (i.e., oper-
ating room and ICU hours, working minutes of surgeons,
nurses, use of suture materials, stapling devices, units of
